Preventing and limiting minimal residual disease following targeted cancer therapy
Bidragets beskrivning
While targeted therapy has transformed the treatment of cancer, the long-term efficacy of these strategies is severely compromized by drug resistance. In the center stage of this process is the ability of some cancer cells to adapt to drug treatment and lay dormant for long period of time. Clinically this phenomenon is observed as minimal residual disease in most patients treated with targeted therapies. The aim of this reserach is to investigate the means cancer cells use to adapt to drug treatment and understand how residual tumor cells modulate the immune system during residual disease. The ultimate goal is to identify vulnerabilities in residual cancer cells, or in the mechanisms that allow the establishment of residual disease, in order to develop combination treatments that will prevent residual disease. This could significantly improve the long-term efficacy of cancer treatments.
Visa merStartår
2021
Slutår
2026
Beviljade finansiering
Andra beslut
361970
Akademiforskarens forskningskostnader(2024)
199 465 €
346656
Akademiforskarens forskningskostnader(2021)
300 000 €
Finansiär
Finlands Akademi
Typ av finansiering
Akademiforskare
Utlysning
Övriga uppgifter
Finansieringsbeslutets nummer
338466
Vetenskapsområden
Biomedicinska vetenskaper
Forskningsområden
Biolääketieteet
Identifierade teman
cancer